New Uthever NMN Clinical Trial Finds NMN Increases NAD+ By 38%, Reduces Insulin Resistance, and Improves Quality of Life

Rate this article

average: 0 out of 5)

average: 0 out of 5)

Rate this article

ProHealth Uthever NMN Clinical Trial Results
  • This clinical trial tested the effects of Uthever NMN in a group of 66 healthy adults between the ages of 40 and 65.

  • The participants were supplemented with either 300 mg NMN per day for 60 days or placebo.

  • After 30 days, the Uthever NMN group already showed a substantial increase in NAD+/NADH levels, at 11.3% above baseline, whereas the placebo group showed no increase.

  • After 60 days, the results were even greater — the Uthever NMN group increased NAD+/NADH levels by 38% from baseline, while the placebo group increased their levels by 14.3%.

  • These results show that ProHealth Uthever NMN is the only NMN clinically proven to boost NAD+ in humans.

  • Further, the Uthever NMN group showed a 6.5% increase in scores on questions about quality of life and physical functioning, compared to 3.4% in the placebo group.

  • Lastly, the Uthever NMN group improved insulin sensitivity, as measured by the HOMA IR Index. Compared to the placebo group, which increased their insulin resistance by 30.6%, the NMN group only saw a rise of 0.6%, indicating much greater insulin sensitivity.

This abstract was published in the journal Frontiers in Aging in March 2022:

Objective: The purpose of the study was to evaluate the anti-ageing effect of NMN and its safety in a double-blind, parallel, randomized controlled clinical trial.

Methods: The study was carried out in 66 healthy subjects between ages 40 to 65 years, instructed to take two capsules (each containing 150 mg. NMN or starch powder) once a day after breakfast for 60 days daily.

Results: At day 30 NAD+/NADH levels in the serum showed noteworthy increase i.e. by 11.3% whereas the placebo group had shown no change at all. At end of study i.e. day 60 the NAD+/NADH levels were increased further by 38% compared to baseline against mere 14.3% in the placebo group. In case of SF 36, at day 60 the Uthever group showed a rise of 6.5% whereas the placebo group was merely raised by 3.4%. At the end of the study, mean HOMA IR Index showed a rise of 0.6% among Uthever group and 30.6% among Placebo group from baseline.

Conclusion: The rise in the levels of NAD+/NADH at Day 30 and Day 60 illustrated the potential of Uthever to raise the levels of NAD+ in the cells, which is linked to higher energy levels and anti-aging effect. Increased sensitivity to insulin has also been linked to anti-aging. There was no noteworthy change in HOMA score in the Uthever group whereas there was a noteworthy rise in the placebo group, demonstrating the anti-aging effect of Uthever as in its absence the parameter worsened.

Rate this article

Rate this article

Share This Article

Share your Comments
Enrich and inform our Wellness Community. Your opinion matters!